Assessment of Metabolic Response to Radioimmunotherapy with Y-90-Ibritumomab Tiuxetan in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (Articolo in rivista)

Type
Label
  • Assessment of Metabolic Response to Radioimmunotherapy with Y-90-Ibritumomab Tiuxetan in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (Articolo in rivista) (literal)
Anno
  • 2010-01-01T00:00:00+01:00 (literal)
Alternative label
  • Storto, G; De Renzo, A; Pellegrino, T; Perna, F; De Falco, T; Erra, P; Nardelli, A; Speranza, A; Klain, M; Rotoli, B; Pace, L (2010)
    Assessment of Metabolic Response to Radioimmunotherapy with Y-90-Ibritumomab Tiuxetan in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
    in Radiology
    (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori
  • Storto, G; De Renzo, A; Pellegrino, T; Perna, F; De Falco, T; Erra, P; Nardelli, A; Speranza, A; Klain, M; Rotoli, B; Pace, L (literal)
Pagina inizio
  • 245 (literal)
Pagina fine
  • 252 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume
  • 254 (literal)
Rivista
Note
  • ISI Web of Science (WOS) (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni
  • IBB CNR (literal)
Titolo
  • Assessment of Metabolic Response to Radioimmunotherapy with Y-90-Ibritumomab Tiuxetan in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (literal)
Abstract
  • To prospectively compare the assessment of metabolic response to yttrium 90 ((90)Y)-ibritumomab tiuxetan radioimmunotherapy (RIT) by using fluorine 18 ((18)F)fluorodeoxyglucose (FDG) combined positron emission tomographic-computed tomographic (PET/CT) imaging at 2 and 6 months to determine the most appropriate time to detect therapeutic response in refractory non-Hodgkin lymphoma (NHL) patients treated with RIT. Materials and Methods: The ethical committee of the university approved the protocol and all patients signed informed consent. Twenty-three consecutive patients (10 women, 13 men; mean age, 51.8 years +/- 7.3 [standard deviation]) treated by using RIT for relapsed or refractory follicular NHL were enrolled. For all patients, (18)F FDG PET/CT scanning was performed at baseline and at 2 and 6 months after RIT. Response was assessed by using the International Workshop Criteria (IWC) and revised criteria (IWC + PET) as well as the criteria of the European Organization for Research and Treatment of Cancer. One-way analysis of variance for repeated measures, receiver operator curve analysis, and Kaplan-Meier curves were used for statistical analysis. Results: PET/CT performed at 2 months revealed complete (n = 12) or partial (n = 4) metabolic response in 16 of 23 patients with complete or partial clinical response. These findings were all confirmed at 6-month scanning. PET/CT indicated refractory or persistent disease at 2 and 6 months in the remaining seven patients. Better overall survival was observed for patients with a reduction in the maximum standard uptake value of 49% or higher (both at 2 and 6 months after RIT) when compared with those with a decrease of less than 49% (P < .05). Conclusion: Early assessment of response to RIT by using PET/CT might be useful in the identification of patients needing additional therapeutic strategies. (C) RSNA, 2010 (literal)
Prodotto di
Autore CNR

Incoming links:


Autore CNR di
Prodotto
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi
data.CNR.it